Mast cells as a therapeutic target in myeloproliferative neoplasms

Marcelo A S Toledo; Nicolas Chatain; Martin Zenke; Steffen Koschmieder

doi:10.1016/j.molmed.2022.08.008

Mast cells as a therapeutic target in myeloproliferative neoplasms

Trends Mol Med. 2022 Nov;28(11):902-905. doi: 10.1016/j.molmed.2022.08.008. Epub 2022 Sep 2.

Authors

Marcelo A S Toledo¹, Nicolas Chatain², Martin Zenke², Steffen Koschmieder²

Affiliations

¹ Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Faculty of Medicine, RWTH Aachen University, Aachen, Germany; Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), Aachen, Germany. Electronic address: Marcelo.Szymanski@rwth-aachen.de.
² Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Faculty of Medicine, RWTH Aachen University, Aachen, Germany; Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), Aachen, Germany.

PMID: 36064534
DOI: 10.1016/j.molmed.2022.08.008

Abstract

Mast cells have been implicated as mediators of bone marrow fibrosis and pruritus in myeloproliferative neoplasms (MPNs) with JAK2V617F or calreticulin mutations. We hypothesize that potent KIT inhibitors, already in clinical use for systemic mastocytosis, have therapeutic potential for the treatment of MPNs by directly targeting mast cells.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Humans
Mast Cells
Mastocytosis, Systemic* / drug therapy
Mastocytosis, Systemic* / genetics
Mutation
Myeloproliferative Disorders* / drug therapy
Myeloproliferative Disorders* / genetics